- Current report filing (8-K)
25 March 2009 - 11:06PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
March 25,
2009
ALLOS THERAPEUTICS, INC.
(Exact name of registrant as specified in its
charter)
Delaware
|
|
000-29815
|
|
54-1655029
|
(State
or other jurisdiction
|
|
(Commission
|
|
(IRS
Employer
|
of
incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
|
|
|
|
|
11080 CirclePoint Road, Suite 200
Westminster, Colorado
|
|
80020
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrants telephone number, including area code:
(303) 426-6262
Not applicable
(Former name or former address, if changed since
last report.)
Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see
General Instruction A.2. below):
o
Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Section 8 Other Events
Item 8.01
Other Events.
On March 25, 2009,
Allos Therapeutics, Inc., a Delaware corporation (the Company), issued a
press release announcing that the Company has submitted a New Drug Application
to the U.S. Food and Drug Administration for the use of pralatrexate for the
treatment of patients with relapsed or refractory peripheral T-cell
lymphoma.
The press release is
attached hereto as Exhibit 99.1 and incorporated herein by reference.
Section 9 Financial Statements and Exhibits
Item 9.01
Financial Statements and
Exhibits.
(d) Exhibits
99.1
|
Press
Release, dated March 25, 2009, entitled Allos Therapeutics Submits New Drug Application for Pralatrexate for
Patients with Relapsed or Refractory Peripheral T-cell Lymphoma.
|
2
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Dated: March 25,
2009
|
|
|
ALLOS
THERAPEUTICS, INC.
|
|
|
|
|
|
|
|
|
|
|
By:
|
/s/
Marc H. Graboyes
|
|
|
|
Marc
H. Graboyes
|
|
|
Its:
|
Senior
Vice President, General Counsel and Secretary
|
3
EXHIBIT INDEX
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Press
Release, dated March 25, 2009, entitled Allos Therapeutics Submits New Drug Application for Pralatrexate for
Patients with Relapsed or Refractory Peripheral T-cell Lymphoma.
|
4
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jul 2023 to Jul 2024